Average Insider

Where insiders trade, we follow

$ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Healthcare
Sector
Biotechnology
Industry
Matthew Gline
CEO
908
Employees
$27.70
Current Price
$19.67B
Market Cap
52W Low$8.73
Current$27.7087.8% above low, 12.2% below high
52W High$30.33

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells22$6,848,573.48241,861
2 weeksBuys00--All Sells
Sells22$6,848,573.48241,861
1 monthBuys00--All Sells
Sells33$23,007,672.38829,251
2 monthsBuys00--All Sells
Sells722$201,146,591.637,458,654
3 monthsBuys00--All Sells
Sells829$249,735,149.199,671,253
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Mar 17, 2026
Venker Eric
President & Immunovant CEO
Sale200,000$28.24$5,648,000.00View Details
Mar 16, 2026
Epperly Melissa B,
Director
Sale41,861$28.68$1,200,573.48View Details
Feb 20, 2026
Torti Frank
President and Vant Chair
Sale1,012,610$27.15$27,492,361.50View Details
Feb 19, 2026
Torti Frank
President and Vant Chair
Sale1,400,000$27.42$38,388,000.00View Details
Feb 23, 2026
Torti Frank
President and Vant Chair
Sale587,390$27.51$16,159,098.90View Details
Feb 13, 2026
Venker Eric
President & Immunovant CEO
Sale200,000$26.49$5,298,000.00View Details
Feb 12, 2026
MANCHESTER KEITH S
Director
Sale150,000$26.72$4,008,000.00View Details
Feb 12, 2026
MANCHESTER KEITH S
Director
Sale275,000$26.76$7,359,000.00View Details
Feb 13, 2026
MANCHESTER KEITH S
Director
Sale225,000$26.50$5,962,500.00View Details
Feb 13, 2026
MANCHESTER KEITH S
Director
Sale150,784$26.49$3,994,268.16View Details
Feb 11, 2026
MANCHESTER KEITH S
Director
Sale425,000$26.67$11,334,750.00View Details
Feb 13, 2026
Gold Daniel Allen
Director
Sale150,784$26.49$3,994,268.16View Details
Feb 13, 2026
Gold Daniel Allen
Director
Sale225,000$26.50$5,962,500.00View Details
Feb 12, 2026
Gold Daniel Allen
Director
Sale150,000$26.72$4,008,000.00View Details
Feb 11, 2026
Gold Daniel Allen
Director
Sale425,000$26.67$11,334,750.00View Details
Feb 12, 2026
Gold Daniel Allen
Director
Sale275,000$26.76$7,359,000.00View Details
Feb 12, 2026
QVT Financial LP
Director by Deputization
Sale150,000$26.72$4,008,000.00View Details
Feb 12, 2026
QVT Financial LP
Director by Deputization
Sale275,000$26.76$7,359,000.00View Details
Feb 13, 2026
QVT Financial LP
Director by Deputization
Sale225,000$26.50$5,962,500.00View Details
Feb 11, 2026
QVT Financial LP
Director by Deputization
Sale425,000$26.67$11,334,750.00View Details

Upcoming Earnings

Scheduled earnings reports
May 27, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Feb 9, 2026
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
Feb 6, 2026
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.3.23